GSK's depemokimab gets EMA nod for asthma and nasal polyps
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...
pharmaphorum3d
FDA says no to AZ's Fasenra for nasal polyp indication
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
GSK says asthma and nasal polyps therapy under EU review
GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...
Too Old to Operate4d
Role of IL-25 in B Cell Activation in Type 2 Inflammatory Disorders
Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor,” published in the January 2025 issue of Allergy ...
Medscape17d
Controversies in the Treatment of Chronic Rhinosinusitis
[102] However, antihistamines are recommended for those patients with nasal polyps associated with atopy. Controversies See the section on antihistamines in CRS without NP. Indication There are no ...
News Medical on MSN14d
Granzyme K+ CD8+ T-cells identified as key drivers of recurrent airway inflammation
Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent respiratory diseases.
Pharmabiz3d
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...